NOVARTIS logo.jpg
New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity
June 16, 2022 01:15 ET | Novartis Pharma AG
COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband...
NOVARTIS logo.jpg
Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
July 20, 2021 07:05 ET | Novartis Pharma AG
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and...
NOVARTIS logo.jpg
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
October 28, 2020 02:15 ET | Novartis International AG
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against...
NOVARTIS logo.jpg
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
April 02, 2020 17:05 ET | Novartis International AG
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm  Cytokine storm is a type of severe immune overreaction that can result from coronavirus...